Bristol-Myers Squibb announced late-breaking results from the UNITY Trial program with all-oral daclatasvir (DCV) TRIO regimen, a fixed-dose combination of daclatasvir with asunaprevir (ASV) and beclabuvir (BCV) in patients with genotype 1 hepatitis C virus (HCV).

The Phase 3 UNITY clinical trial program is an ongoing study investigating 12-week regimens of the DCV-TRIO fixed-dose combination. The open-label UNITY-1 study evaluated a 12-week regimen of the DCV-TRIO without ribavirin in treatment-naïve and -experienced non-cirrhotic patients. Non-cirrhotic treatment-naïve patients (n=312) and treatment-experienced patients (n=103) received the DCV-TRIO fixed-dose combination in one pill twice daily for 12 weeks, with 24 weeks of follow-up. The majority of the patients (73%) were genotype 1a, and 91% of all patients achieved SVR12. Ninety-two percent of treatment-naive patients and 89% of treatment-experienced patients achieved cure, without the use of ribavirin.

RELATED: DCV Dual Regimen Designated Breakthrough Therapy for Chronic Hepatitis C

In the UNITY-2 study, both cirrhotic treatment-naïve and treatment-experienced patients received the DCV-TRIO fixed-dose combination, one arm without ribavirin (n=102) and one with ribavirin (n=100). The study was double-blinded to ribavirin, and the majority of the patients (74%) were genotype 1a. The study showed 96% of all patients who received the DCV-TRIO with ribavirin achieved SVR12, and 90% of those who received the DCV-TRIO without ribavirin achieved SVR12.

Continue Reading

The primary endpoint for both studies was the percentage of patients who achieved cure, defined as HCV RNA

For more information call (800) 321-1335 or visit